| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| systematic review | Q1504425 |
| review article | Q7318358 |
| P2093 | author name string | Yu Zheng | |
| Xiao-Gang Ren | |||
| Xu-Qing Zhu | |||
| P2860 | cites work | Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival | Q85785131 |
| Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial | Q87206964 | ||
| Improving trends in survival of patients who receive chemotherapy for metastatic or recurrent gastric cancer: 12 years of experience at a single institution | Q87885346 | ||
| Quantifying heterogeneity in a meta-analysis | Q27860672 | ||
| Cancer statistics, 2014 | Q27861018 | ||
| Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program | Q30313895 | ||
| Chemotherapy treatment patterns, costs, and outcomes of patients with gastric cancer in the United States: a retrospective analysis of electronic medical record (EMR) and administrative claims data | Q30912750 | ||
| Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer | Q33407797 | ||
| Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer | Q33488159 | ||
| Incidence and mortality of gastric cancer in China | Q33829885 | ||
| Progression-free survival as a surrogate endpoint for overall survival in patients with third-line or later-line chemotherapy for advanced gastric cancer | Q35541950 | ||
| Prognostic factors of second and third line chemotherapy using 5-fu with platinum, irinotecan, and taxane for advanced gastric cancer | Q35661060 | ||
| Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. | Q35927364 | ||
| Outcomes of third-line docetaxel-based chemotherapy in advanced gastric cancer who failed previous oxaliplatin-based and irinotecan-based chemotherapies | Q36536982 | ||
| Prevalence and trends of receipt of cancer screenings among US women with diagnosed diabetes | Q37067775 | ||
| Paclitaxel plus valproic acid versus paclitaxel alone as second- or third-line therapy for advanced gastric cancer: a randomized Phase II trial | Q37138570 | ||
| Safety and continuity of second- and third-line therapy with paclitaxel or irinotecan for advanced and recurrent gastric cancer | Q38956887 | ||
| A three-year survivor case of gastric cancer with peritoneal dissemination--an outpatient with second-line weekly paclitaxel. | Q39317028 | ||
| Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients | Q39320938 | ||
| Efficacy and safety of irinotecan monotherapy as third-line treatment for advanced gastric cancer. | Q39448583 | ||
| Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction | Q39991776 | ||
| Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). | Q42608504 | ||
| Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 400 | Q44754243 | ||
| Efficacy and safety of docetaxel or epirubicin, combined with cisplatin and fluorouracil (DCF and ECF), regimens as first line chemotherapy for advanced gastric cancer: a retrospective analysis from Turkey. | Q44994262 | ||
| Combination chemotherapy with 5-fluorouracil, cisplatin and paclitaxel for pretreated patients with advanced gastric cancer. | Q46922379 | ||
| Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer. | Q48208260 | ||
| Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. | Q53384216 | ||
| Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. | Q53604465 | ||
| A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer. | Q54390371 | ||
| Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer. | Q54571851 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International | Q24082749 |
| P433 | issue | 24 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | systematic review | Q1504425 |
| antineoplastic | Q2853144 | ||
| stomach neoplasm | Q4335552 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | e6884 | |
| P577 | publication date | 2017-06-01 | |
| P1433 | published in | Medicine | Q15716652 |
| P1476 | title | Third-line chemotherapy in advanced gastric cancer: A systematic review and meta-analysis | |
| P478 | volume | 96 |
| Q90409938 | A Review of Research Progress in Multidrug-Resistance Mechanisms in Gastric Cancer |
| Q90643923 | Delivery rate of patients with advanced gastric cancer to third-line chemotherapy and those patients' characteristics: an analysis in real-world setting |
| Q90629947 | Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical Trial |
| Q64952998 | Efficacy and Safety of Xiao Ai Ping Injection Combined with Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis. |
| Q93135012 | Late-line treatment in metastatic gastric cancer: today and tomorrow |
| Q90568939 | Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300 |
| Q94546944 | Role of Systemic Treatment for Advanced/Metastatic Gastric Carcinoma in the Third-Line Setting: A Bayesian Network Analysis |
| Q93138804 | Trifluridine/Tipiracil: A Review in Metastatic Gastric Cancer |
Search more.